During the past decade, GUZ "Oncological Dispesary #2" conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 2 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "GUZ "Oncological Dispesary #2"" are "Breast Neoplasms" (1 trials) and "Carcinoma, Non-Small-Cell Lung" (1 trials). Many other conditions were trialed in "GUZ "Oncological Dispesary #2"" in a lesser frequency.

Most popular intervention types in "GUZ "Oncological Dispesary #2"" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Afatinib 40mg once daily (OD)" (1 trials), "BIBF 1120 plus docetaxel" (1 trials), "Paclitaxel 80 mg/m2 weekly" (1 trials), "Vinorelbine 25 mg/m2 weekly" (1 trials) and "placebo plus docetaxel" (1 trials). Other intervention names were less common.

The vast majority of trials in "GUZ "Oncological Dispesary #2"" are 1 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "GUZ "Oncological Dispesary #2"". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in GUZ "Oncological Dispesary #2", undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in GUZ "Oncological Dispesary #2", 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".

GUZ "Oncological Dispesary #2" has several departments that took part in Clinical trials: "Oncologic Dispensary No.2" - 25 trials